Andere Sprachen Supernus Pharmaceuticals, Inc.

Aktien

A1JX3U

US8684591089

SUPN

Realtime-Estimate Cboe BZX Andere Börsenplätze 15:46:21 01.05.2024			% 5 Tage	% 1. Jan.
30,36 ^USD	+0,88 %		+0,50 %	+4,01 %

08.04.	Supernus' Zulassungsantrag für Parkinson-Pumpe Apomorphin erleidet FDA-Rückschlag; Aktien fallen vorbörslich	MT
08.04.	Supernus Pharmaceuticals, Inc. gibt ein Zulassungs-Update für SPN-830 bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story	14:01
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors	30.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN	28.04.
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024	24.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN	20.04.
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	08.04.
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	08.04.
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	08.04.
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08.04.
Supernus Provides Regulatory Update for SPN-830	08.04.
Supernus Provides Regulatory Update for SPN-830	08.04.
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	25.03.
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	21.03.
Supernus to Participate in Two Upcoming Investor Conferences	06.03.
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference	28.02.
Supernus: Q4 Earnings Snapshot	28.02.
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	27.02.
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	27.02.
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Supernus Pharmaceuticals, Inc.

Aktien

A1JX3U

US8684591089

SUPN

Andere Sprachen

Filter